Overview

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, toxicity and efficacy of talactoferrin in reducing the incidence of all nosocomial infections in prematurely-born infants.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Agennix
Collaborator:
National Institutes of Health (NIH)
Treatments:
Lactoferrin
Talactoferrin alfa